# Diagonal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/diagonal-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.diagonaltx.com
- Total disclosed funding: $150M
- Latest round: Series B (Jan 8, 2026)
- Investors on record: 19

## About

Based in Massachusetts, US, and founded in 2022, Diagonal Therapeutics, Inc. develops agonist antibodies by combining patented computational and experimental methods. In January 2026, Diagonal Therapeutics, Inc. raised USD 125 million in series B funding co-led by returning investors BVF Partners and Atlas Venture, with participation from other returning investors RV Invest, Frazier Healthcare Partners, Checkpoint Capital, Lightspeed Venture Partners, RA Capital, Velosity Capital, and Viking Global Investors. New investors Biovision Ventures, Sanofi Ventures, Logos Capital, Deep Track Capital, EcoR1 Capital, Woodline Partners, Janus Henderson Investors, and other unspecified investors also participated in the round. As of 2024 the company is led by CEO Alex Lugovskoy.


Diagonal Therapeutics' proprietary platform, Diagonal's, utilizes a combination of computational and experimental techniques to identify agonist antibodies. The platform enables the generation of deep immune repertoires and the development of multispecific antibodies, allowing for the exploration of over 10 billion possible combinations. The company's pipeline includes promising candidates targeting a range of diseases, including hereditary hemorrhagic telangiectasia (HHT), pulmonary arterial hypertension (PAH), and solid tumors.


The company plans to use the April 2024 funding to further develop its platform and boost its drug pipeline.

## Funding rounds

- Series B, Jan 8, 2026, $125M — Atlas Venture, Frazier Healthcare Partners, Lightspeed Venture Partners, Viking Global Investors, Sanofi Ventures, BVF Partners, EcoR1 Capital, Janus Henderson Investors, Logos Capital, Deep Track Capital, Biovision Ventures, Balyasny Asset Management L.P., Woodline Partners, Checkpoint Capital, RV Invest, Velosity Capital, RA Capital
- Series A, Apr 3, 2024, $25M — Atlas Venture, Lightspeed Venture Partners, Viking Global Investors, BVF Partners, RA Capital Management, Frazier Life Sciences Management, Lp, Checkpoint Capital, Velosity Capital
- Seed, Jun 1, 2022 — Atlas Venture, Lightspeed Venture Partners, Velosity Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A, Series B
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed, Series A, Series B
- Velosity Capital — Seed, Series A, Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Frazier Life Sciences Management, Lp — Series A
- Checkpoint Capital — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Janus Henderson Investors — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- Biovision Ventures (https://capitalatlas.ai/funds/biovision-ventures) — Series B
- Balyasny Asset Management L.P. — Series B
- Woodline Partners — Series B
- RV Invest (https://capitalatlas.ai/funds/rv-invest) — Series B
- RA Capital — Series B